The Ophthalmic Pharmaceutical Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts - 2009/09/03 - Business Insights

Report title: The Ophthalmic Pharmaceutical Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts

from Business Insights
158 page report published Sep 03, 2009

Price $3,835.00 available for immediate download

Report Overview

Table of Contents

Search Inside

About Business Insights

IntroductionThe $13.5bn global ophthalmic pharmaceutical market demonstrated low double-digit y-o-y growth in 2008. The emergence of treatment strategies for age-macular degeneration and the subsequent therapeutic and commercial success of Lucentis has led to a substantial rise in overall size of the market while signaling the lucrative and expanding sector within ophthalmology. However, the market faces a patent cliff post 2010 due to patent expiries of class-leading products in anti-glaucoma, ocular anti-allergic and anti-infective/anti-inflammatory therapies. Subsequent generic incursion coupled with the increasing legislative priority towards healthcare reform across the globe will hurt market expansion and growth of ophthalmic franchises of leading pharmaceutical companies. Driven by good efficacy, Roche/Genentech's Lucentis and Allergan/Inspire's Restasis is expected to dominate the treatment of wet AMD and dry eye markets respectively. However Business Insights expect worldwide sales of ophthalmology treatments to remain roughly flat during 2008-14.Key findings
- The ophthalmic pharmaceutical market registered sales of $13.5bn in 2008, at a y-o-y increase of 13.3%. The top ten ophthalmic brands accounted for $6.6bn sales or 49.0% share of the market in 2008.
- Anti-glaucoma preparations formed the largest category in 2008, posting $5.2bn sales. The segment grew at 11.0% y-o-y, accounting for 38.7% market share. Pfizer's Xalatan dominated this segment while delivering sales of $1.6bn. The segment is expected to post a CAGR of -9.7% during 2008-2014.
- Ocular antineovascularization preparations, used for the treatment of wet AMD, accounted for $1.8bn in sales during 2008. The segment captured 13.4% of the market, while registering a robust y-o-y growth of 29.8%. Roche/Novartis' Lucentis dominated the market with $1.6bn sales during the same year. The segment will be one of the major growth drivers for the market with CAGR of 6.7% during 2008-14.Key features of this report
- Estimation of target population in leading ophthalmic indications that offer high commercial prospects such as cataract, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema (DME) and dry eye syndrome in the ophthalmic pharmaceutical sector.
- Company analysis and market share of the top eight players in the ophthalmic pharmaceutical market: Alcon, Allergan, Pfizer, Novartis, Roche, Merck, Santen Seiyaku and Bausch & Lomb.
- Overview of key events in the ophthalmic pharmaceutical market that have impacted treatment trends and sales potential across indications.
- In-depth analysis of the ophthalmic pharmaceutical pipelineUse this report to
- Quantify the epidemiological status of cataract, glaucoma, AMD and dry eye syndrome in the US, 5EU and Japan.
- Understand therapy segments with the greatest franchise growth potential and understand the growth drivers.
- Compare the franchises of top ophthalmic pharmaceutical players across major indications, and evaluate how market share of leading companies such as Alcon, Allergan, Pfizer, Novartis, Roche, Merck, Santen Seiyaku and Bausch & Lomb will evolve over the next five years.Discover
- What will be the major growth indications and the accompanying growth drivers in the ophthalmic pharmaceutical market over 2008'14?
- What are the current trends within the major segments such as glaucoma, retinal disorders (AMD, DME, etc.), dry eye syndrome, ophthalmic infections and inflammation, etc.?
- What are the most promising ophthalmic products in clinical development and their forecast commercial potential through 2014?
- Which companies are best positioned to succeed in the ophthalmic pharmaceutical market over the period 2008'14?

Source:

Business Insights

Document ID:

rbhc0238

Industry:

Pharmaceutical

Free Sample:

Click Here to Download

Format:

PDF

Title	Starting Page	Number of Pages
Sections
Table of Contents The Ophthalmic Pharmaceutical Market Outlook to 2014 Executive summary 12 Overview and epidemiology 12 Global market analysis 13 Pipeline analysis 14 Competitive landscape 15 Chapter 1 Scope and methodology 18 Scope 18 Methodology 19 Chap	0	1
Table of Contents	0	1
The Ophthalmic Pharmaceutical Market Outlook to 2014	0	1
Executive summary 12	0	1
Overview and epidemiology 12	0	1
Global market analysis 13	0	1
Pipeline analysis 14	0	1
Competitive landscape 15	0	1
Chapter 1 Scope and methodology 18	0	1
Scope 18	0	1
Methodology 19	0	1
Chapter 2 Overview and epidemiology 22	0	1
Summary 22	0	1
Introduction 23	0	1
Blindness facts 23	0	1
Cataracts 25	0	1
Background 25	0	1
Treatment and management 25	0	1
Forecast epidemiology 27	0	1
Glaucoma 28	0	1
Background 28	0	1
Treatment and management 28	0	1
Forecast epidemiology 31	0	1
Retinal disorders 32	0	1
Age-related macular degeneration 32	0	1
Treatment and management 33	0	1
Forecast epidemiology 34	0	1
Diabetic retinopathy and diabetic macular edema 36	0	1
Treatment and management 37	0	1
Epidemiology 37	0	1
Dry eye syndrome or (keratoconjunctivitis sicca) 38	0	1
Background 38	0	1
Treatment and management 38	0	1
Forecast epidemiology 39	0	1
Chapter 3 Global market analysis 42	0	1
Summary 42	0	1
Introduction 43	0	1
Historical growth trends 43	0	1
Regional dynamics 45	0	1
Leading ophthalmic brands 46	0	1
Market analysis by drug class 47	0	1
Forecast market performance drug class wise 49	0	1
Key issues 50	0	1
Patent cliff looms in the ophthalmic market 50	0	1
Key events 52	0	1
Anti-glaucoma preparations 54	0	1
Leading brands 55	0	1
Brand analysis 55	0	1
Leading players 58	0	1
Ocular anti-neovascularization preparations 59	0	1
Leading brands 59	0	1
Brand analysis 60	0	1
Leading players 64	0	1
Artificial tears 64	0	1
Leading brands 65	0	1
Brand analysis 65	0	1
Leading players 67	0	1
Ocular anti-allergics, decongestants and antiseptics 67	0	1
Drug class analysis 68	0	1
Leading brands 69	0	1
Brand analysis 69	0	1
Leading players 70	0	1
Ophthalmic anti-infectives and anti-inflammatory preparations 71	0	1
Drug class analysis 72	0	1
Leading anti-infective brands 73	0	1
Key brand analysis 73	0	1
Leading anti-inflammatory brands 74	0	1
Key brand analysis 74	0	1
Leading anti-infectives/anti-inflammatory combination brands 76	0	1
Key brand analysis 76	0	1
Leading players 78	0	1
Miscellaneous ophthalmic preparations 78	0	1
Leading brands 79	0	1
Chapter 4 Pipeline analysis 82	0	1
Summary 82	0	1
Introduction 83	0	1
Key trends, issues and events 83	0	1
Protracted regulatory pathway presents entry barriers to the highgrowth DES segment 83	0	1
Drug implant techniques: economic alternative to laser therapy in DME 84	0	1
AMD treatment that uses VEGF-targeted siRNA strategies is in troubled waters 86	0	1
Recently launched products 88	0	1
Besivance 88	0	1
Ozurdex 88	0	1
Products in Phase III 89	0	1
Bepreve 89	0	1
Prolacria 90	0	1
VEGF Trap-Eye 92	0	1
Luveniq 94	0	1
Products in Phase II 94	0	1
iDestrin 94	0	1
Ecabet 95	0	1
Androgen Tears 96	0	1
Pipeline forecasts 97	0	1
Chapter 5 Competitive landscape 100	0	1
Summary 100	0	1
Introduction 101	0	1
Market concentration/fragmentation analysis 101	0	1
Sales performance of leading players 102	0	1
Positioning of major players in 2008 by segment 103	0	1
Forecast sales performance of leading players 104	0	1
Alcon 105	0	1
Overview 105	0	1
Dependency on ophthalmic business 105	0	1
Drug class focus 106	0	1
Marketed portfolio 108	0	1
Pipeline portfolio 109	0	1
Competitive analysis 110	0	1
Allergan 113	0	1
Overview 113	0	1
Dependency on ophthalmic business 114	0	1
Drug class focus 115	0	1
Marketed portfolio 116	0	1
Pipeline portfolio 117	0	1
Competitive analysis 119	0	1
Pfizer 122	0	1
Overview 122	0	1
Dependency on ophthalmic business 123	0	1
Drug class focus 124	0	1
Marketed portfolio 125	0	1
Pipeline portfolio 126	0	1
Competitive analysis 127	0	1
Novartis 128	0	1
Overview 128	0	1
Dependency on ophthalmic business 128	0	1
Drug class focus 129	0	1
Marketed portfolio 130	0	1
Pipeline portfolio 131	0	1
Competitive analysis 132	0	1

Enter the keyword(s) which you would like to search for within this document and click "Search"

Business Insights provides a single, off-the-shelf, objective source of data, analysis and market insight. Business Insights work in association with leading industry experts to produce a range of reports across a wide range of industry sectors.

Price: $3,835.00

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Industry Snapshot

Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.